Jason Pitofsky sold $1.6M of REGN
SVP Controller at REGENERON PHARMACEUTICALS, INC.. 2,036 shares at an average of $778.52, traded Feb 9, 2026, filed Feb 11, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.6M at market
- +10Share of holdings soldSold 32% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.1%, 3m -7.5%, 6m +2.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002009236-26-000001, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 9, 2026 | MOption exercise Common Stock10b5-1 | +1,000 | $492.00 | $492k | 6,308 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -20 | $775.95 | $16k | 6,288 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -521 | $776.43 | $405k | 5,767 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -391 | $777.51 | $304k | 5,376 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -563 | $778.35 | $438k | 4,813 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -205 | $779.56 | $160k | 4,608 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -75 | $780.06 | $59k | 4,533 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -26 | $781.37 | $20k | 4,507 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -37 | $782.67 | $29k | 4,470 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -144 | $783.23 | $113k | 4,326 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1 | $784.66 | $785 | 4,325 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -53 | $785.72 | $42k | 4,272 | Feb 11, 2026 |
| Feb 9, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -1,000 | $0.00 | $0 | 905 | Feb 11, 2026 |
Related signals
Other insiders at REGENERON PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $340k 400 shares | -40% | |
| 33Weak | REGENERON PHARMACEUTICALS, INC. | Marion McCourt EVP Commercial | $2.0M 2,346 shares | -16% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $320k 400 shares | -40% | |
| 18Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $640k 800 shares | -32% | |
| 6Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $130k 200 shares | -1% | |
| 3Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $71k 100 shares | -1% | |
| 4Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $78k 100 shares | -1% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $79k 100 shares | -1% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $1.3M 1,638 shares | -49% | |
| 19Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $78k 100 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.